Local Institution - 115

New York, New York 10065

0 studies enrolling now · 2 studies all time

What they study most

Multiple Myeloma, Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis

Studies at this site

• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) — Completed
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib — Stopped early